Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience

Research output: Contribution to journalArticle

Abstract

Aim: Immunotherapy opened new frontiers in metastatic non-small-cell lung cancer treatment, but not all patients benefit from it. Methods: We retrospectively evaluated 65 metastatic non-small-cell lung cancer patients, treated with nivolumab, considering as disadvantaged subgroups those with poor performance status, elderly, patients with brain metastases at baseline, with high disease burden and refractory to platinum. Results: No differences in overall survival or time to treatment failure were found according to performance status, age, presence of brain metastases at baseline or high disease burden. Conversely, patients refractory to platinum had a statistically significant shorter overall survival and time to treatment failure. At multivariate analysis only platinum resistance was confirmed as an independent predictive factor. Conclusion: Our study suggests that only refractoriness to platinum salts influence the efficacy of nivolumab.

Original languageEnglish
Pages (from-to)945-952
Number of pages8
JournalImmunotherapy
Volume11
Issue number11
DOIs
Publication statusPublished - Aug 2019

Fingerprint Dive into the research topics of 'Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience'. Together they form a unique fingerprint.

  • Cite this